{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-034684","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.067641+00:00","generated_at":"2026-06-13T07:47:18.495854+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BridgeBio Phase 3 acoramidis hits primary endpoint in ATTR-CM; NDA planned by year-end 2023","bullets":["Primary endpoint met with Win Ratio 1.8 (p<0.0001); 81% on-treatment survival vs 74% placebo.","50% relative risk reduction (p<0.0001) in frequency of cardiovascular-related hospitalization.","All secondary endpoints (NT-proBNP, KCCQ, 6-min walk) statistically significant at 30 months (p<0.0001).","No safety signals identified; NDA submission to FDA targeted by end of 2023.","Exploratory analysis suggests 42% greater increase in serum TTR vs tafamidis; 92% improvement in median NT-proBNP."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-034684","json":"https://secwatch.observer/filing/0001140361-23-034684.json","markdown":"https://secwatch.observer/filing/0001140361-23-034684.md","text":"https://secwatch.observer/filing/0001140361-23-034684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036123034684/0001140361-23-034684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036123034684/brhc20055953_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:47:18.495854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}